SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 7, 2013
TRIUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
6310 Nancy Ridge Drive, Suite 105
San Diego, CA
(Address of principal executive offices)
Registrants telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On January 7, 2013, Trius Therapeutics, Inc. issued a press release presenting the balance of its cash, cash equivalents, and investments as of December 31, 2012. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
On January 7, 2013, Trius Therapeutics, Inc. issued a press release to announce the designation by the Food and Drug Administration of its lead investigational drug candidate, tedizolid phosphate, as a Qualified Infectious Disease Product (QIDP). A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INDEX TO EXHIBITS